LivaNova (United Kingdom)

Recent papers from LivaNova (United Kingdom)

1. Durability of Implanted Cervical Vagus Nerve Stimulation in Treatment-resistant Major Depression: Summary of Findings and Potential Mechanisms of ActionCurrent Addiction Reports · 2026
2. The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, and Future DirectionsAmerican Journal of Psychiatry · 2026
3. A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic HealthCPT Pharmacometrics & Systems Pharmacology · 2026
4. EHMN2026®T: A License-Aware AI-QSP Integration Framework Linking EHMN2026® with TRANSFAC®, TRANSPATH® and HumanPSD™ for Diagnostic-Metabolite InterpretationMetabolites · 2026
5. Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven reviewDrug Discovery Today · 2026
6. D97-09 False Positive Responses in Hypoglossal Nerve Stimulation Clinical TrialsAmerican Journal of Respiratory and Critical Care Medicine · 2026
7. Effectiveness and safety of implantable vagus nerve stimulation in people with primary generalized tonic–clonic seizuresEpilepsia Open · 2026
8. Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY StudyAnnals of Internal Medicine · 2026
9. EHMN 2026: A Thermodynamically Refined, SBML-Standardised Human Metabolic Network for Genome-Scale Analysis and QSP IntegrationMetabolites · 2026
10. Assessing symptom severity in patients with markedly treatment-resistant depression: Insights from the RECOVER trialJournal of Affective Disorders · 2026
11. CORE-VNS: Dosing and titration of VNS therapy in contemporary clinical practiceEpilepsy & Behavior Reports · 2026
12. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial reportThe International Journal of Neuropsychopharmacology · 2025
13. Assessing an fMRI-guided titration paradigm for microburst VNS therapyEpilepsy Research · 2026
14. Healthcare Utilization and Cost in the Two Years Before Neuromodulation Implantation Among Medicaid Enrollees with Drug-Resistant EpilepsyClinicoEconomics and Outcomes Research · 2025
15. Specialized AI and neurosurgeons in niche expertise: a proof-of-concept in neuromodulation with vagus nerve stimulationActa Neurochirurgica · 2025
16. An examination of symptoms, function and quality of life as conjoint clinical outcome domains for treatment-resistant depressionJournal of Mood and Anxiety Disorders · 2025
17. Reduction of generalized tonic–clonic seizures following vagus nerve stimulation therapy: CORE ‐ VNS Study 24‐month follow‐upEpilepsia · 2025
18. Characterizing the effects of vagus nerve stimulation on symptom improvement in markedly treatment-resistant major depressive disorder: A RECOVER trial reportJournal of Affective Disorders · 2025
19. Titration of vagus nerve stimulation for difficult-to-treat depression and onset of response: Early insights from the RESTORE-LIFE studyJournal of Affective Disorders · 2025
20. Impact of Vagus Nerve Stimulation for the Treatment of Drug-resistant Epilepsy on Patterns of Use and Cost of Healthcare Services and Pharmacotherapy Among Medicare Enrollees: Findings From Analyses of Healthcare Claims From the Centers of Medicare and Medicaid ServicesClinical Therapeutics · 2025